Connect with us
Prague Gaming & TECH Summit 2024

Artificial Intelligence

Digital Biomanufacturing Market – Distribution by Type of Technology, Deployment Options, Types of Biologics Manufactured, and Key Geographical Regions: Industry Trends and Global Forecasts, 2023-2035

Published

on

<!– Name:DistributionId Value:8846618 –> <!– Name:EnableQuoteCarouselOnPnr Value:False –> <!– Name:IcbCode Value:5557 –> <!– Name:CustomerId Value:1199811 –> <!– Name:HasMediaSnippet Value:false –> <!– Name:AnalyticsTrackingId Value:ccb78ce4-a7aa-43c2-80ac-8fdaaa3e84a0 –>

New York, May 25, 2023 (GLOBE NEWSWIRE) — Reportlinker.com announces the release of the report “Digital Biomanufacturing Market – Distribution by Type of Technology, Deployment Options, Types of Biologics Manufactured, and Key Geographical Regions: Industry Trends and Global Forecasts, 2023-2035” – https://www.reportlinker.com/p06458562/?utm_source=GNW
Further, a surge in morbidity across the globe and enhanced interconnectivity of equipment and technologies has led to an increased burden on manufacturing operations. Other factors that influenced the market include higher competition, competitive pricing, inflation rate, technological advancements and evolving regulatory guidelines. These factors demanded a fundamental shift from conventional manufacturing operations, which subsequently led to the introduction of industry 4.0 technologies. Digital biomanufacturing has emerged as a promising alternative to mitigate a number of bioprocessing related concerns, as well as significantly promote process robustness and product quality.

Digital biomanufacturing, popularly known as bioprocessing 4.0, refers to the integration of physical equipment with digital software and platforms, such as process analytical technologies (PAT), data analysis software (DAS), manufacturing execution systems (MES) and digital twins, in order to streamline the overall biomanufacturing process. Implementation of these technologies in monitoring, analytics and computing capabilities is expected to revolutionize current biomanufacturing practices. Further, digital bioprocessing is believed to have transformed manufacturing principles in areas, such as process development, operational activities, logistics and supply chain management, when used in combination with advanced technologies, including artificial intelligence (AI), machine learning and internet of things (IoT).

SCOPE OF THE REPORT
The Digital Biomanufacturing Market: Distribution by Type of Technology (PAT, DAS, MES and Digital Twins), Deployment Options (Cloud-based and On-premises), Type(s) of Biologic(s) Manufactured (Antibodies, Cell Therapies and Gene Therapies, Proteins, Vaccines, and Others), and Key Geographical Regions (North America, Europe, Asia-Pacific, Latin America, and Middle East and North Africa): Industry Trends and Global Forecasts, 2023-2035 report features an extensive study of the current market landscape and the likely future potential of the digital biomanufacturing market, over the next 12 years. It highlights the efforts of several stakeholders engaged in this rapidly emerging segment of the pharmaceutical industry. Key inclusions of the report are briefly discussed below:

Growing Demand for Biologics
Breakthroughs in the biotechnology industry, over the last few decades, has provided a considerable boost to the overall development landscape of biopharmaceutical drugs. In 2022, a milestone was witnessed when the number of approvals received by biologics narrowly outpaced those reported by small molecules. Further, in the same year, nearly half of the biologic approvals were allotted to novel class of modalities, including antibody drug conjugates (ADCs), bispecific antibodies, cell therapies and gene therapies. This can be attributed to the fact that the demand for biologics has been constantly increasing and is supported by continuous innovation in this field. Specifically, advancements in niche segments is expected to culminate in accelerated growth of the biologics market.

Need for Digital Biomanufacturing
According to a recent report, the development of a new drug takes 10-15 years, with an overall investment of USD 1-2 billion. Despite the significant investment of resources, over 90% of the candidates fail at different stages of clinical trials, resulting in huge financial losses for biomanufacturers.

As a direct consequence of the consistently growing demand for biologics and the existing challenges, there is an increase in the requirement for solutions that help in establishment of a digitally enabled and connected end-to-end process, in order to optimize bioprocess operations. Research suggests that, at present, 20% of the organizations have already adopted digitalized approaches for biomanufacturing. Such approaches are expected to enable an uninterrupted and accessible supply of cost-effective drugs that are likely to be launched commercially, with reduced development timelines. In fact, several leading biopharma players have claimed to achieve 40% increase in quality, 15% reduction in cost, 80% decrease in process variability and 20% shorter operational timelines by leveraging digital biomanufacturing advances. , , ,

Key Advantages of Digital Biomanufacturing
Currently, batch-to-batch variation and product validation are considered as major bottlenecks faced by the biologic industry. Digital biomanufacturing harnesses various advancements, such as real-time monitoring, data analytics, automation, modelling, process optimization and other digital tools to transform the available information into actionable insights. This is expected to help in the creation of a uniform process, which is capable of decreasing the deviation in quality of each batch. Other key benefits of digital biomanufacturing include improved efficiency, higher product yield, better product quality, data integrity, reduced manual intervention and limited risk of contamination. It is worth noting that digitalization in biopharmaceutical manufacturing is becoming an essential requirement, given its potential to develop enhanced quality products, with high speed, agility and sustainability.

Current Market Landscape of Digital Biomanufacturing
The digital biomanufacturing providers landscape features a mix of large, mid-sized and small companies, which have the required expertise and offer various digital services for the production of biologics. At present, more than 140 digital technologies have been / are being developed by over 100 industry stakeholders to enable the manufacturing of biologics. Further, various types of technologies currently facilitate smart biomanufacturing; of these, 48% are based on the principles of PAT, followed by those using MES (28%), DAS (14%) and digital twins (10%).

Key Trends in the Digital Biomanufacturing Market
Many stakeholders are undertaking initiatives to forge alliance with other industry / non-industry players. It is worth highlighting that over 75 strategic partnerships related to digital biomanufacturing have been inked since 2018, indicating that software providers are actively upgrading their technology related capabilities and accommodating the current and anticipated demand for digital biomanufacturing. Given the inclination towards cutting-edge technologies, along with innovative approaches to tailor the bioprocessing, we believe that the digital biomanufacturing technologies market is likely to evolve at a rapid pace, over the coming years. ,

Market Size of the Digital Biomanufacturing Market
Driven by improved data analytics, better product yield, faster production timelines, access to real time operations and rising interest in paperless manufacturing amongst innovators, lucrative opportunities are expected to emerge for players offering bioprocessing 4.0 services. The digital biomanufacturing market is anticipated to grow at a CAGR of 11%, during the period 2023-2035. In terms of type of technology, the digital biomanufacturing market for digital twins is expected to grow at a relatively faster pace (19%), till 2035. Further, currently, the market for on-premise deployment options is expected to capture the majority share, however, this trend is likely to change in the foreseen future with the rising popularity of cloud-based technologies.

Example Players in the Digital Biomanufacturing Market
Examples of players engaged in this domain include (which have also been captured in this report) AspenTech, Bioreactors.net, Dassault Systèmes, FUJIFILM Diosynth Biotechnologies, GE Healthcare, Körber, Merck, Sartorius and Thermo Fisher Scientific.

The report presents an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain, across different regions. Amongst other elements, the report includes:
An executive summary of the insights captured during our research, offering a high-level view on the current state of the digital biomanufacturing market and its likely evolution in the mid-long term.
A general introduction to digital biomanufacturing, featuring a detailed discussion on various types of technologies that support digital bioprocessing. In addition, it presents the key challenges and future perspectives associated with the employment of digital technologies in the field of biomanufacturing.
A detailed assessment of the overall market landscape of companies offering digital biomanufacturing technologies (PAT, DAS, MES and digital twins), based on several relevant parameters, such as year of establishment, company size (in terms of number of employees), location of headquarters, type of company (CDMO provider and software provider), number of platforms offered, deployment options (cloud based, on-premises, corporate datacenter and hybrid), platform capabilities (process automation, bioprocess optimization and controls, process connectivity, scalability, data integration, process monitoring and visualization, performance analysis, report generation and documentation, smart manufacturing, document control, production tracking, performance analysis and data integration), software capabilities (process intelligence, data integration, real-time process monitoring, data visualization, performance analysis and control prediction, reporting and data management), type(s) of biologic(s) manufactured, other compatible platforms (artificial intelligence / machine learning / cloud based, big data, internet of things, augmented reality and virtual reality) and type of end user(s) (industry and non-industry), integrating software (enterprise resource planning (ERP), manufacturing operation management (MOM), product lifecycle management (PLM), human resource management (HRM)), type of service(s) offered (training, implementation / upgradation and general support), area(s) of application (asset / process management, clinical trials, personalized treatment, medical training, surgical planning, health monitoring and diagnosis).
A detailed competitiveness analysis of digital biomanufacturing technologies (PAT, DAS, MES and digital twins), based on supplier strength (in terms of years of experience and company size), technology portfolio (considering deployment options, number of platform capabilities, type of end user(s), software capabilities, area(s) of application, type(s) of twin(s)) and type(s) of biologic(s) manufactured.
Elaborate profiles of key players (companies offering more than one platform and established before 2012) engaged in the digital biomanufacturing domain, which are actively providing software based on PAT, DAS, MES and digital twins. Each profile includes a brief overview of the company, along with information on capabilities of digital technologies offered by these firms, recent developments and an informed future outlook.
A benchmark analysis highlighting the capabilities of companies (in terms of their expertise across various platforms related to the manufacturing of biologics) engaged in this domain, across key peer groups.
An analysis featuring information on recent partnerships inked between stakeholders engaged in this domain, based on several relevant parameters, such as year of partnership, type of partnership, type of technology, most active players (in terms of number of deals inked) and regional distribution of partnership activity, during the period 2018-2022.
A detailed analysis highlighting the market concentration of key industry stakeholders (companies offering more than one platform) across various regions, based on prevalent parameters, such as years of entrance, company size, type of technology, number of platforms offered and number of partnerships inked.
A detailed industry lifecycle analysis that indicates various stages, including emergence, growth, maturation and eventual decline for the digital biomanufacturing industry. The primary purpose of this analysis is to develop a better understanding of the current position / phase of the industry on the lifecycle chart (based on historical trends, partnership activity and various investments made by players engaged in this domain) and predict the upcoming events that are likely to drive the growth of this domain. Further, it presents short-term and long-term impacts of various key parameters that are expected to highly impact the wider adoption of digitalization in the field of biomanufacturing.

One of the key objectives of the report was to estimate the current opportunity and future growth potential of the digital biomanufacturing market. We have provided an informed estimate on the likely evolution of the market for the period, 2023-2035. Our year-wise projections of the current and forecasted opportunity have been further segmented based on relevant parameters, such as type of technology (PAT, DAS, MES and digital twins), deployment options (cloud based and on-premises), type(s) of biologic(s) manufactured (antibodies, cell therapies and gene therapies, proteins, vaccines and others) and key geographical regions (North America, Europe, Asia-Pacific, Middle East and North Africa, and Latin America). In order to account for future uncertainties associated with some of the key parameters and to add robustness to our model, we have provided three market forecast scenarios, portraying the conservative, base and optimistic scenarios of the industry’s evolution.

The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders in this domain. The report features detailed transcripts of interviews held with the following individuals:
Joel Sirois (President and Chief Executive Officer, BioIntelligence Technologies)
Klaus Mauch (Managing Director and Chief Executive Officer, Yokogawa Insilico Biotechnology)
Ciaran O’Keeffe (Director, Business Development and Channel Sales, MasterControl) and Isura Sirisena (Quality and Manufacturing Digitization Specialist, MasterControl)
Yaron Halfon (Director of Sales, Trunovate)
Barbara Holtz (Business Consultant, Dassault Systèmes)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

RESEARCH METHODOLOGY
The data presented in this report was gathered via primary and secondary research. For all our projects, we conduct interviews / surveys with reputed domain experts (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and technology segments. Wherever possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include:
Annual reports
Investor presentations
SEC filings
Industry databases
News releases from company websites
Government policy documents
Industry analysts’ views

While the focus has been on forecasting the market till 2035, the report also provides our independent view on various technological and non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.

KEY QUESTIONS ANSWERED
Question 1: What is the global market size of digital biomanufacturing?
Answer: The current global digital biomanufacturing market is anticipated to be worth around USD 15 billion.

Question 2: Which are the top players in the global digital biomanufacturing market?
Answer: Presently, more than 100 companies are engaged in digital biomanufacturing, worldwide. The top players engaged in this domain (which have also been captured in this report) include AspenTech, Bioreactors.net, Dassault Systèmes, FUJIFILM Diosynth Biotechnologies, GE Healthcare, Körber, Merck, Sartorius and Thermo Fisher Scientific.

Question 3: What are the factors driving the digital biomanufacturing market?
Answer: Increasing number of approved biologics, growing number of biologics-related clinical trials, rise in R&D activity and a shift in preference for cloud-based processes, over the traditional biomanufacturing operations, has bolstered the demand for digital biomanufacturing software.

Question 4: Which region has the highest market share in the global digital biomanufacturing market?
Answer: North America and Europe capture around 75% share in the current global digital biomanufacturing market, followed by Asia-Pacific.

Question 5: What are the leading market segments in digital biomanufacturing market?
Answer: Currently, in terms of type of technology, process analytical technology captures the largest share (close to 50%) in the global digital biomanufacturing market. However, digital twins are likely to witness higher annual growth rates in the upcoming years, owing to their rising popularity. Further, in terms of type of company, software providers hold the largest share in the digital biomanufacturing market as compared to CDMOs.

Question 6: Which segment, in terms of deployment options, accounts for the largest share in the global digital biomanufacturing market?
Answer: At present, the global biomanufacturing market is dominated by the players providing on-premises deployment options, while the market is anticipated to shift towards the use of cloud-based technologies in the near future.

Question 7: What are the partnership and collaboration trends in the digital biomanufacturing domain?
Answer: At present, service alliances, technology utilization agreements and acquisitions are the most prominent types of partnerships inked between various stakeholders engaged in the digital biomanufacturing domain.

Question 8: What is the growth rate (CAGR) in the global digital biomanufacturing market?
Answer: The global digital biomanufacturing market size is projected to grow at a CAGR of ~11% in the coming years.

CHAPTER OUTLINES

Chapter 1 is a preface providing an introduction to the full report, Digital Biomanufacturing Market, 2023-2035.

Chapter 2 is an executive summary of the insights captured during our research, offering a high-level view on the current state of the digital biomanufacturing market and its likely evolution in the mid-long term.

Chapter 3 provides a general introduction to digital biomanufacturing. It further includes a detailed discussion on the various types of technologies that support digital bioprocessing. In addition, it presents the key challenges and future perspectives associated with the employment of digital technologies in the field of biomanufacturing.

Chapter 4 includes a detailed assessment of the overall market landscape of companies offering digital biomanufacturing technologies (PAT, DAS, MES, digital twins), based on several relevant parameters, such as year of establishment, company size (in terms of number of employees), location of headquarters, type of company (CDMO provider and software provider), number of platforms offered, deployment options (cloud based, on-premises, corporate datacenter and hybrid), platform capabilities (process automation, bioprocess optimization and controls, process connectivity, scalability, data integration, process monitoring and visualization, performance analysis, report generation and documentation, smart manufacturing, document control, production tracking, performance analysis and data integration), software capabilities (process intelligence, data integration, real-time process monitoring, data visualization, performance analysis and control prediction, reporting and data management), area(s) of application (asset / process management, clinical trials, personalized treatment, medical training, surgical planning, health monitoring and diagnosis), integrating software (enterprise resource planning (ERP), manufacturing operation management (MOM), product lifecycle management (PLM), human resource management (HRM)), type of service(s) offered (training, implementation / upgradation and general support), type(s) of biologic(s) manufactured, other compatible platforms (artificial intelligence / machine learning / cloud based, big data, internet of things, augmented reality and virtual reality) and type of end user(s) (industry and non-industry).

Chapter 5 presents a detailed competitiveness analysis of digital biomanufacturing technologies (PAT, DAS, MES and digital twins) based on company strength (in terms of years of experience and company size), technology portfolio (considering deployment options, number of platform capabilities, type of end user(s), software capabilities, area(s) of application, type(s) of twin(s)), and type(s) of biologic(s) manufactured.

Chapter 6 features elaborate profiles of key players (companies offering more than one platform and established before 2012) engaged in the digital biomanufacturing domain, which are actively providing software based on PAT, DAS, MES and digital twins. Each profile includes a brief overview of the company, along with information on the capabilities of digital technologies offered by these firms, recent developments and an informed future outlook.

Chapter 7 presents benchmark analysis of the capabilities of companies (in terms of their expertise across various platforms related to the manufacturing of biologics) engaged in this domain, across key peer groups.

Chapter 8 features information on recent partnerships inked between stakeholders engaged in this domain, based on several relevant parameters, such as year of partnership, type of partnership, type of technology, most active players (in terms of number of deals inked) and regional distribution of partnership activity, during the period 2018-2022.

Chapter 9 highlights our opinion on the market concentration of key industry stakeholders (companies offering more than one platform) across various regions, based on prevalent parameters, such as years of entrance, company size, type of technology, number of platforms offered and number of partnerships inked.

Chapter 10 presents a detailed industry lifecycle analysis that indicates various stages, including emergence, growth, maturation and eventual decline for the digital biomanufacturing industry. The primary purpose of this analysis is to develop a better understanding of the current position / phase of the industry on the lifecycle chart (based on historical trends, partnership activity and various investments made by players engaged in this domain) and predict the upcoming events that are likely to drive the growth of this domain. Further, it presents short-term and long-term impacts of various key parameters that are expected to highly impact the wider adoption of digitalization in the field of biomanufacturing.

Chapter 11 presents a comprehensive market forecast analysis, highlighting the future potential of the market till 2035. Our year-wise projections of the current and forecasted opportunity have been further segmented based on relevant parameters, such as type of technology (PAT, DAS, MES and digital twins), deployment options (cloud based and on-premises), type(s) of biologic(s) manufactured (antibodies, cell therapies and gene therapies, proteins vaccines, and others), and key geographical regions (North America, Europe, Asia-Pacific, Middle East and North Africa, and Latin America).

Chapter 12 is a summary of the overall report. The chapter provides the key takeaways from the report, and presents facts and figures described in the previous chapters. The chapter also highlights important evolutionary trends that were identified during the course of the study and are expected to influence the future of the digital biomanufacturing market.

Chapter 13 is a collection of transcripts of interviews conducted with various stakeholders in the industry. We have presented details of interviews held Joel Sirois (President and Chief Executive Officer, BioIntelligence Technologies), Klaus Mauch (Managing Director and Chief Executive Officer, Yokogawa Insilico Biotechnology), Ciaran O’Keeffe (Director, Business Development and Channel Sales, MasterControl), Isura Sirisena (Quality and Manufacturing Digitization Specialist, MasterControl), Yaron Halfon (Director of Sales, Trunovate) and Barbara Holtz (Business Consultant, Dassault Systèmes).

Chapter 14 is an appendix, which contains tabulated data and numbers for all the figures included in this report.

Chapter 15 is an appendix, which contains a list of companies and organizations mentioned in this report.
Read the full report: https://www.reportlinker.com/p06458562/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need – instantly, in one place.

__________________________


GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Artificial Intelligence

Confluence former executive joins fintech Premialab

Published

on

confluence-former-executive-joins-fintech-premialab

James Carrington, a former executive at Confluence, Investment Metrics, Style Analytics has joined fintech Premialab. He brings extensive client engagement expertise in investment analytics and data for the institutional investment community.
LONDON, Feb. 27, 2024 /PRNewswire/ — Premialab, the financial data and analytics firm, announced today the appointment of James Carrington as Head of Client Engagement. Mr. Carrington, based in London, will spearhead global client engagement, leveraging over 10 years of experience in driving client engagement gained at Investment Metrics, Style Analytics, and most recently at Confluence, part of the Clearlake Capital Group portfolio. His primary focus will be on enabling faster tailor-made investment analytics delivery and data integration for Premialab’s pension funds, foundations, endowments, and insurance clients.

Adrien Geliot, Co-Founder & Chief Executive Officer of Premialab, said, “I am delighted to welcome James to the team. His appointment confirms our commitment to delivering first-class service to our customers across global locations. His experience in maximizing the value derived from investment analytics will be invaluable in serving our clients as we continue scaling our activities worldwide.”
Commenting on his appointment, James Carrington said, “I am delighted to have joined the Premialab team. Their innovative solution makes a real difference to institutional investors looking at quant investments. The evolution of Premialab over the last number of years has been something that I have followed closely, and I am looking forward to working with the team to further support our customer base across our established and emerging demographics.”
The announcement follows recent senior appointments at Premialab, including Philippe Jacson, former BNP Paribas, Merrill Lynch and MSCI executive; Daniel Fields, former Global Head of Markets at Societe Generale; John Macpherson, former Managing Director at Goldman Sachs, Citibank, and Nomura; Marc Fisher, former Managing Director at Citibank with a prior position at Deutsche Bank; and Georgios Sittas, former Managing Director at HSBC, Standard Chartered, and previously a director at Lehman Brothers.
Recognized as the reference for data and risk analytics on quantitative strategies, Premialab’s capital markets infrastructure is currently used by leading asset managers, insurance companies and pensions funds, accelerating their digitalization and enhancing performance and risk control while reducing costs. The platform’s client AUM is representing an estimated USD$10 trillion.
About Premialab
Premialab is an independent platform providing data, analytics and risk solutions on systematic and factor-based strategies in collaboration with leading investment banks and institutional investors globally. Combining intelligent technology with a unique source of information the platform empowers asset allocators to make better investment decisions whilst achieving utmost time and cost efficiency.
With offices in London, Paris, New York, Hong Kong, Sydney, and Dubai, its international team is dedicated to supporting a global client base with the most up-to-date risk premia dataset, advanced portfolio construction, performance and risk analytics. The firm has established strong partnerships with the top 18 investments banks, global asset managers, pensions funds and insurance companies.

View original content:https://www.prnewswire.co.uk/news-releases/confluence-former-executive-joins-fintech-premialab-302071655.html

Continue Reading

Artificial Intelligence

Axon Technologies and Keyrus Announce Strategic Partnership to Elevate Cybersecurity Business

Published

on

axon-technologies-and-keyrus-announce-strategic-partnership-to-elevate-cybersecurity-business

Keyrus Acquires Minority Stake in Axon Technologies, adding Axon’s Cybersecurity Portfolio to Keyrus Solutions, and Expanding Keyrus Reach across Middle East and Africa
PARIS and DUBAI, UAE, Feb. 27, 2024 /PRNewswire/ — In a significant development in the cybersecurity sector, Keyrus, an international leader in data intelligence and digital transformation, has announced the acquisition of a minority stake in Axon Technologies, a premier provider of cybersecurity services based in Dubai, UAE. This strategic investment marks a major milestone in Keyrus’ cybersecurity strategy, signalling an ambitious step towards establishing a global cybersecurity powerhouse.

Strategic Expansion and Enhanced Cybersecurity Solutions
The collaboration between Keyrus and Axon Technologies is set to revolutionize the cybersecurity landscape in the Middle East and Africa, particularly with Keyrus’ entry into the lucrative Saudi Arabian market. This move enables Keyrus to pursue its investment in a newly formed cybersecurity business, offering enhanced data security solutions to both existing and new clients.
Eric Cohen, Founder and CEO of Keyrus, expressed his enthusiasm: “This investment in Axon Technologies marks a significant step in our cybersecurity strategy. We’re embarking on an exciting journey to amplify our cybersecurity capabilities and establish a world-class global player in this domain. Axon Technologies’ innovative approach to consulting and managed services aligns perfectly with our vision and culture. We eagerly anticipate integrating Axon into our ecosystem to bolster our cybersecurity solutions and address the digital security challenges of our clients.”
Hadi Hosn, CEO of Axon Technologies, also shared his thoughts: “This partnership marks a new era for Axon Technologies, propelling us further in our mission to protect organizations from cyber threats. We admire the Keyrus vision and believe that our combined strengths will lead to disruptive data and cybersecurity solutions, addressing critical challenges in digital identity, application security, API, and data security across various environments and industries.”
Hadi Darwiche, Chairman of DIV Capital & Co-founder of Axon Technologies: “It’s gratifying to see Axon Technologies grow from a concept into a key player in the cybersecurity field. With Keyrus joining forces with us, we anticipate a period of sustained growth, leveraging our combined experience and established reputations. We are confident that together, Axon Technologies will continue to extend its market presence and deliver top-tier solutions.”
Comprehensive Cybersecurity Portfolio and Global Reach
In a relatively short period, Axon Technologies, founded in 2020, has emerged as a beacon of excellence and innovation in the cybersecurity field, demonstrating remarkable growth and agility in its operations. With a revenue of $3.2 million USD in 2023 and a projected substantial increase of the activities, it represents a testament to its robust business model, exceptional service delivery, and the trust clients place in Axon Technologies. The team made of 30 dedicated professionals is its most valuable asset. Axon Technologies commits to growing its team, fostering a culture of innovation, collaboration, and continuous learning.
Axon Technologies, renowned for its expertise in cybersecurity, will now be able to leverage Keyrus global presence and capabilities. With headquarters in Dubai and a significant footprint in the Middle East, Europe and Africa, Axon Technologies is well-positioned to monitor threats and support client cybersecurity programs across these regions effectively. With the backing of Keyrus’s global network, Axon Technologies is poised for unprecedented growth and are dedicated to setting new standards in the cybersecurity landscape.
The partnership is also expected to enhance the offerings of both companies. Axon Technologies’ expertise in Data Security, Cloud Security, DevSecOps and Managed Security Services aligns seamlessly with the Keyrus strategic objectives in digital, data, AI and cloud transformation initiatives.
About Axon Technologies
Axon Technologies offers comprehensive cybersecurity services including consulting, managed security services, engineering, and testing. The company is a leader in addressing critical infrastructure customers’ cybersecurity needs, from strategic consulting to hands-on management and technical security engineering support and managed security services, ensuring a robust and comprehensive approach to cybersecurity. The company’s service portfolio includes:
Technical Security Consulting & Advisory: Guidance and expertise for technical cybersecurity programs.Advanced Security Testing: Rigorous cybersecurity testing across the environment to identify and address vulnerabilities.Security Engineering & Architecture: Designing and implementing robust security architectures across on-premises and cloud environments.Managed Security Services: Ongoing management and support of cybersecurity operations. About Keyrus
Keyrus, an international player in the consulting and technology sectors and a specialist in data and digital technology, is dedicated to helping enterprises take advantage of the data and digital paradigm to enhance their performance, facilitate and accelerate their transformation, and generate new drivers of growth and competitiveness.
Placing innovation at the heart of its strategy, Keyrus develops a value proposition that is unique in the market and centred around five major service groups, each comprised of multiple solutions:
Automation and Artificial IntelligenceHuman-Centric Digital ExperienceData and Analytics enablementCloud and SecurityBusiness transformation and InnovationBuilding on the combined expertise of more than 3,500 employees active across 27 countries and 4 continents, Keyrus is one of the leading international experts in data, consulting and technology.
Keyrus is listed on Euronext Growth Paris. (ALKEY – ISIN Code: FR0004029411 – Reuters: KEYR.PA – Bloomberg: ALKEY: FP).
About DIV Capital
DIV Capital, originally starting as a family office, now operating as a strategic investment holding firm, specializing in bespoke advisory services. The firm focuses on fortifying family capital through comprehensive offerings that encompass support for early-stage enterprises, strategic asset allocation, and robust governance infrastructure development. The firm operates out of Geneva and Dubai and provides three core services:
Family Asset Support: Tailored support to construct an asset allocation that meets wealth goals.Family Financial Sponsorship: Reinforcement for family-operated businesses, aimed at fostering enduring value creation.Governance and Reporting: Consultation on governance frameworks and the enhancement of reporting standards for comprehensive asset oversight.Forward Looking Statements
Some of the statements in this press release may be forward-looking statements or statements of future expectations based on currently available information. Such statements are naturally subject to risks and uncertainties. Factors such as the development of general economic conditions, future market conditions, unusual catastrophic loss events, changes in the capital markets and other circumstances may cause the actual events or results to be materially different from those anticipated by such statements. Axon Technologies, Keyrus or DIV Capital do not make any representation or warranty, express or implied, as to the accuracy, completeness or updated status of such statements. Therefore, in no case whatsoever will the companies and the affiliate companies be liable to anyone for any decision made or action taken in conjunction with the information and/or statements in this press release or for any related damages.
Contact: [email protected]
Logo – https://mma.prnewswire.com/media/1659746/Keyrus_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/axon-technologies-and-keyrus-announce-strategic-partnership-to-elevate-cybersecurity-business-302071417.html

Continue Reading

Artificial Intelligence

NDC Group and Valantic form a strategic partnership in EPM solutions

Published

on

ndc-group-and-valantic-form-a-strategic-partnership-in-epm-solutions

PRAGUE, Feb. 27, 2024 /PRNewswire/ — NDC Group, a leading company in enterprise performance management (EPM) consultancy and data analytics is pleased to announce a strategic partnership with valantic, renowned digital solutions, consulting, and tech innovation company. Through this partnership, the companies aim to offer a joint portfolio of solutions and services in SAP planning and analytics.

Central to this collaboration is the delivery of NDC Financial Consolidation, which offers an automated and streamlined approach to legal and managerial consolidation. While the solution draws inspiration from the concept and functions of previously popular SAP consolidation solutions, it utilizes the modern technologies to enhance automation, performance, user experience, and seamless data integration.
The partnership also gives the chance to offer additional products, including SAC workforce planning content, SAP BusinessObjects migration accelerators, and pre-built content for SAC financial planning. Overall, the combined expertise and product offering enhance the ability of both companies to support customers in driving data-driven transformations within their organizations.
Stefan Blinkmann, Head of SAP Analytics at valantic, emphasizes: “We are very pleased about our new partnership, and we are convinced that our customers will benefit greatly from it. Above all, the NDC Group’s products create added value in the area of consolidation based on SAP Analytics Cloud, and they expand valantic’s range of services. An integrated solution for reporting, planning, and consolidation in SAP Analytics Cloud provides multiple benefits for our customers and enables them to streamline their system landscape.”
Karel Jirik, Head of Products at NDC Group, is also convinced of the benefits of this collaboration: “Our partnership with valantic is an excellent opportunity to leverage the synergies between our teams to streamline and transform our customers’ data landscape. The jointly offered EPM solutions enable precise and swift decision-making and enhance operational efficiency, crucial elements in today’s competitive landscape. I’m particularly pleased we found a lot of commonalities with valantic, and I am convinced together we can deliver better solutions in a shorter time.”
Vladislav Stefanak, CEO of NDC Group, reflects on the partnership’s potential: “This partnership embodies my vision of equipping our clients with advanced functionalities reminiscent of those found in SAP BPC and SAP Financial Consolidation, yet significantly enhanced by leveraging top-tier SAP technologies. Our collaboration with valantic commenced with remarkable synergy from the outset, underpinned by their extensive expertise and knowledge base.”
Photo – https://mma.prnewswire.com/media/2341827/NDC_Coop_Valantic.jpg

View original content:https://www.prnewswire.co.uk/news-releases/ndc-group-and-valantic-form-a-strategic-partnership-in-epm-solutions-302064148.html

Continue Reading

Trending